GlassScriptPhysician profile
Anthony W Delorenzo
NPI 1851477236
$7,022.03
in general payments reported to CMS, 2019-2025
39 companies · $705 in 2025
The $705 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,268 · 2020: $816 · 2021: $1,309 · 2022: $838 · 2023: $1,223 · 2024: $861 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,779 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.81 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $904.38 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $810.93 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbvie INC. | $661.76 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $604.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $449.66 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Corcept Therapeutics | $448.31 | 2023-2025 | Korlym |
| Allergan, INC. | $330.38 | 2019-2020 | |
| Lilly USA, LLC | $285.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $276.91 | 2019-2025 | |
| Esperion Therapeutics, INC. | $241.25 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $200.82 | 2019-2025 | |
| Abbott Laboratories | $185.33 | 2021-2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $176.36 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $156.93 | 2019-2023 | Spravato |
| Edwards Lifesciences Corporation | $154.87 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Delorenzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.